Immune cell therapy shows promise in brain cancer battle

NCT ID NCT00807027

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times

Summary

This phase 3 trial tested whether adding an immune cell therapy called Immuncell-LC to standard chemotherapy (temozolomide) helps people with newly diagnosed glioblastoma, an aggressive brain cancer. The study enrolled 180 adults aged 18-70 who had surgery for glioblastoma. Researchers measured how long patients lived without the cancer getting worse and overall survival. The goal was to see if the combination treatment works better than chemotherapy alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Gyunghee University Medical Center

    Seoul, South Korea

  • Hanyang University Guri Hospital

    Guri-si, Gyeonggi-do, South Korea

  • Konkuk University

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Samsung Seoul Medical Center

    Seoul, South Korea

  • Seoul Asan Medical Center

    Seoul, South Korea

  • Yeonsei University Medical Center

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.